Both global and domestic drug companies are looking to diversify sourcing of Active Pharmaceutical Ingredients and Key Starting Materials from China. Indian companies, particularly pure-play API producers, are poised to tap this emerging opportunity.These five API companies may benefit as drugmakers seek to reduce dependence on Chinese raw material
Both global and domestic drug companies are looking to diversify sourcing of Active Pharmaceutical Ingredients and Key Starting Materials from China. Indian companies, particularly pure-play API producers, are poised to tap this emerging opportunity.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The bank plans to raise up to Rs 500 crore by issue of equity shares to qualified institutional buyers through qualified institutional plac...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment